We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas.
- Authors
Oike, Naoki; Kawashima, Hiroyuki; Ogose, Akira; Hatano, Hiroshi; Ariizumi, Takashi; Yamagishi, Tetsuro; Murayama, Yudai; Umezu, Hajime; Imai, Chihaya; Hayashi, Masanori; Endo, Naoto
- Abstract
The characteristics of the tumor immune microenvironment remains unclear in liposarcomas, and here we aimed to determine the prognostic impact of the tumor immune microenvironment across separate liposarcomas subtypes. A total of 70 liposarcoma patients with three subtypes: myxoid liposarcoma (n = 45), dedifferentiated liposarcoma (n = 17), and pleomorphic liposarcoma (n = 8) were enrolled. The presence of tumor infiltrating lymphocytes (CD4+ , CD8+ , FOXP3+ lymphocytes) and CD163+ macrophages and expression of HLA class I and PD-L1 were assessed by immunohistochemistry in the diagnostic samples; overall survival and progression-free survival were estimated from outcome data. For infiltrating lymphocytes and macrophages, dedifferentiated liposarcoma and pleomorphic liposarcoma patients had a significantly higher number than myxoid liposarcoma patients. While myxoid liposarcoma patients with a high number of macrophages were associated with worse overall and progression-free survival, dedifferentiated liposarcoma patients with high macrophage numbers showed a trend toward favorable prognosis. Expression of HLA class I was negative in 35 of 45 (77.8%) myxoid liposarcoma tumors, whereas all dedifferentiated liposarcoma and pleomorphic liposarcoma tumors expressed HLA class I. The subset of myxoid liposarcoma patients with high HLA class I expression had significantly poor overall and progression-free survival, while dedifferentiated liposarcoma patients with high HLA class I expression tended to have favorable outcomes. Only four of 17 (23.5%) dedifferentiated liposarcomas, two of eight (25%) pleomorphic liposarcomas, and no myxoid liposarcoma tumors expressed PD-L1. Our results demonstrate the unique immune microenvironment of myxoid liposarcomas compared to other subtypes of liposarcomas, suggesting that the approach for immunotherapy in liposarcomas should be based on subtype.
- Subjects
LIPOSARCOMA; HLA histocompatibility antigens; TUMOR-infiltrating immune cells; OVERALL survival; PROGRESSION-free survival; DIAGNOSTIC immunohistochemistry
- Publication
Cancer Immunology, Immunotherapy, 2021, Vol 70, Issue 12, p3489
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-021-02928-1